Company news

Oculis Holding AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oculis Publishes Results of 2025 Annual General Meeting

June 4, 2025

Oculis to Participate in Upcoming June Investor Conferences

June 2, 2025

Oculis Publishes Invitation to the Annual General Meeting

May 8, 2025

Oculis Reports Q1 Financial Results and Provides Company Update

May 7, 2025

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 7, 2025

Oculis to Present at Upcoming May Investor Conferences

May 6, 2025

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

April 30, 2025

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

April 30, 2025

Oculis Updates Share Capital

April 24, 2025

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

April 16, 2025

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

April 14, 2025

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

April 9, 2025

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

April 9, 2025

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

March 31, 2025

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

March 20, 2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

March 14, 2025

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

March 10, 2025

Oculis to Present at Upcoming March Investor Conference

March 4, 2025

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

February 13, 2025

Oculis updates share capital for its existing at-the-market offering program

January 30, 2025

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

January 5, 2025

Oculis Publishes Notification of Major Changes in Voting Rights

January 3, 2025

Oculis to Present at the Stifel 2024 Healthcare Conference

November 12, 2024

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

November 6, 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

October 20, 2024

Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

October 14, 2024

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

October 1, 2024

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

September 18, 2024

Oculis to Present at Upcoming September Investor Conferences

August 28, 2024

Oculis Reports Q2 Financial Results and Provides Recent Company Update

August 26, 2024

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

August 26, 2024

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

August 14, 2024

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

July 29, 2024

Oculis and EURETINA Announces the Ramin Tadayoni Award

June 26, 2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

June 9, 2024

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

May 29, 2024

Oculis Holding - Increase in share capital

May 20, 2024

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

May 7, 2024

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

May 7, 2024

Oculis to Present at Bank of America Global Healthcare Conference

May 5, 2024

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

April 21, 2024

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

April 10, 2024

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

April 9, 2024

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

April 7, 2024

Oculis to Participate at Upcoming April Investor Conferences

April 3, 2024

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

March 17, 2024

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

February 27, 2024

Oculis to Present at Upcoming February Investor Conferences

January 28, 2024

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

January 21, 2024

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

December 19, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 15 decks. Every deck is listed under its year.